• Je něco špatně v tomto záznamu ?

Biosimilar Candidate CT-P42 in Diabetic Macular Edema: 24-Week Results from a Randomized, Active-Controlled, Phase III Study

S. Wolf, PE. Stanga, M. Veselovsky, M. Veith, A. Papp, S. Mange, L. Kanta Mondal, D. Romanczak, L. Janco, R. Chauhan, B. Romanowska-Dixon, A. Eremina, N. Zavgorodnya, J. Dusova, M. Sagong, S. Kim, K. Ahn, S. Kim, Y. Bae, S. Lee, H. Kang, DM. Brown

. 2024 ; 8 (12) : 1163-1173. [pub] 20240626

Jazyk angličtina Země Spojené státy americké

Typ dokumentu časopisecké články, klinické zkoušky, fáze III, randomizované kontrolované studie, multicentrická studie

Perzistentní odkaz   https://www.medvik.cz/link/bmc25003325

OBJECTIVE: To demonstrate the therapeutic similarity of CT-P42 compared with reference aflibercept (Eylea) in adult patients with diabetic macular edema (DME). DESIGN: Randomized, active-controlled, double-masked, phase III clinical trial PARTICIPANTS: Patients with a diagnosis of either type 1 or 2 diabetes mellitus with DME involving the center of the macula. METHODS: Patients were randomized (1:1) to receive either CT-P42 or reference aflibercept (2 mg/0.05 ml) by intravitreal injection every 4 weeks (5 doses), then every 8 weeks (4 doses), in the main study period. Results up to week 24 are reported herein. MAIN OUTCOME MEASURES: The primary end point was mean change from baseline at week 8 in best-corrected visual acuity (BCVA) using the ETDRS chart. Equivalence between CT-P42 and reference aflibercept was to be concluded if the 2-sided 95% confidence interval (CI) (global assumptions) and 2-sided 90% CI (United States Food and Drug Administration [FDA] assumptions) for the treatment difference fell entirely within the equivalence margin of ±3 letters, as assessed in the full analysis set. RESULTS: Overall, 348 patients were randomized (CT-P42: 173; reference aflibercept: 175). Best-corrected visual acuity improved from baseline to week 8 in both groups, with a least squares mean (standard error) improvement of 9.43 (0.798) and 8.85 (0.775) letters in the CT-P42 and reference aflibercept groups, respectively. The estimated between-group treatment difference was 0.58 letters, with the CIs within the predefined equivalence margin of ±3 letters (95% CI, -0.73 to 1.88 [global]; 90% CI, -0.52 to 1.67 [FDA]). Through week 24, other efficacy results for the 2 groups, in terms of change in BCVA and retinal central subfield thickness, as well as ETDRS Diabetic Retinopathy Severity Scale score, supported therapeutic similarity. Pharmacokinetics, usability, safety (including the proportions of patients experiencing ≥1 treatment-emergent adverse event [CT-P42: 50.3%; reference aflibercept: 53.7%]), and immunogenicity were also comparable between groups. CONCLUSIONS: This study in patients with DME demonstrated equivalence between CT-P42 and reference aflibercept (2 mg/0.05 ml) in terms of efficacy, with similar pharmacokinetic, usability, safety, and immunogenicity profiles. FINANCIAL DISCLOSURE(S): Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc25003325
003      
CZ-PrNML
005      
20250206104248.0
007      
ta
008      
250121s2024 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.oret.2024.06.013 $2 doi
035    __
$a (PubMed)38942386
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Wolf, Sebastian $u Department of Ophthalmology, Inselspital, Bern University Hospital, Bern, Switzerland; Department of BioMedical Research, Bern, Switzerland
245    10
$a Biosimilar Candidate CT-P42 in Diabetic Macular Edema: 24-Week Results from a Randomized, Active-Controlled, Phase III Study / $c S. Wolf, PE. Stanga, M. Veselovsky, M. Veith, A. Papp, S. Mange, L. Kanta Mondal, D. Romanczak, L. Janco, R. Chauhan, B. Romanowska-Dixon, A. Eremina, N. Zavgorodnya, J. Dusova, M. Sagong, S. Kim, K. Ahn, S. Kim, Y. Bae, S. Lee, H. Kang, DM. Brown
520    9_
$a OBJECTIVE: To demonstrate the therapeutic similarity of CT-P42 compared with reference aflibercept (Eylea) in adult patients with diabetic macular edema (DME). DESIGN: Randomized, active-controlled, double-masked, phase III clinical trial PARTICIPANTS: Patients with a diagnosis of either type 1 or 2 diabetes mellitus with DME involving the center of the macula. METHODS: Patients were randomized (1:1) to receive either CT-P42 or reference aflibercept (2 mg/0.05 ml) by intravitreal injection every 4 weeks (5 doses), then every 8 weeks (4 doses), in the main study period. Results up to week 24 are reported herein. MAIN OUTCOME MEASURES: The primary end point was mean change from baseline at week 8 in best-corrected visual acuity (BCVA) using the ETDRS chart. Equivalence between CT-P42 and reference aflibercept was to be concluded if the 2-sided 95% confidence interval (CI) (global assumptions) and 2-sided 90% CI (United States Food and Drug Administration [FDA] assumptions) for the treatment difference fell entirely within the equivalence margin of ±3 letters, as assessed in the full analysis set. RESULTS: Overall, 348 patients were randomized (CT-P42: 173; reference aflibercept: 175). Best-corrected visual acuity improved from baseline to week 8 in both groups, with a least squares mean (standard error) improvement of 9.43 (0.798) and 8.85 (0.775) letters in the CT-P42 and reference aflibercept groups, respectively. The estimated between-group treatment difference was 0.58 letters, with the CIs within the predefined equivalence margin of ±3 letters (95% CI, -0.73 to 1.88 [global]; 90% CI, -0.52 to 1.67 [FDA]). Through week 24, other efficacy results for the 2 groups, in terms of change in BCVA and retinal central subfield thickness, as well as ETDRS Diabetic Retinopathy Severity Scale score, supported therapeutic similarity. Pharmacokinetics, usability, safety (including the proportions of patients experiencing ≥1 treatment-emergent adverse event [CT-P42: 50.3%; reference aflibercept: 53.7%]), and immunogenicity were also comparable between groups. CONCLUSIONS: This study in patients with DME demonstrated equivalence between CT-P42 and reference aflibercept (2 mg/0.05 ml) in terms of efficacy, with similar pharmacokinetic, usability, safety, and immunogenicity profiles. FINANCIAL DISCLOSURE(S): Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article.
650    _2
$a senioři $7 D000368
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a lidé $7 D006801
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    12
$a inhibitory angiogeneze $x aplikace a dávkování $7 D020533
650    _2
$a biosimilární léčivé přípravky $x aplikace a dávkování $7 D059451
650    12
$a diabetická retinopatie $x farmakoterapie $x diagnóza $x komplikace $7 D003930
650    _2
$a vztah mezi dávkou a účinkem léčiva $7 D004305
650    _2
$a dvojitá slepá metoda $7 D004311
650    _2
$a následné studie $7 D005500
650    _2
$a injekce intravitreální $7 D058449
650    _2
$a macula lutea $x patologie $x diagnostické zobrazování $7 D008266
650    12
$a makulární edém $x farmakoterapie $x diagnóza $x etiologie $7 D008269
650    12
$a receptory vaskulárního endoteliálního růstového faktoru $x aplikace a dávkování $x antagonisté a inhibitory $7 D040262
650    _2
$a rekombinantní fúzní proteiny $x aplikace a dávkování $7 D011993
650    _2
$a časové faktory $7 D013997
650    _2
$a optická koherentní tomografie $x metody $7 D041623
650    _2
$a výsledek terapie $7 D016896
650    _2
$a vaskulární endoteliální růstový faktor A $x antagonisté a inhibitory $7 D042461
650    _2
$a zraková ostrost $7 D014792
655    _2
$a časopisecké články $7 D016428
655    _2
$a klinické zkoušky, fáze III $7 D017428
655    _2
$a randomizované kontrolované studie $7 D016449
655    _2
$a multicentrická studie $7 D016448
700    1_
$a Stanga, Paulo-Eduardo $u The Retina Clinic London, London, United Kingdom; Institute of Ophthalmology, University College London, London, United Kingdom
700    1_
$a Veselovsky, Milan $u Faculty hospital with Policlinic Zilina, Ophthalmology Department, Zilina, Slovakia
700    1_
$a Veith, Miroslav $u Univerzity Hospital Kralovske Vinohrady, Prague, Czech Republic; 3(rd) Faculty of Medicine, Charles University, Prague, Czech Republic
700    1_
$a Papp, Andras $u Semmelweis University Department of Ophthalmology, Budapest, Hungary
700    1_
$a Mange, Shobhana $u Shivam Retina Clinic and Eye Hospital, Surat, India
700    1_
$a Kanta Mondal, Lakshmi $u Regional Institute of Ophthalmology, Kolkata, India
700    1_
$a Romanczak, Dominika $u Centrum Zdrowia MDM, Warszawa, Poland
700    1_
$a Janco, Ladislav $u II. Ocna Klinika SZU, F.D. Roosevelt Hospital, Banska Bystrica, Slovakia
700    1_
$a Chauhan, Rohan $u Rising Retina Clinic, Ahmedabad, India
700    1_
$a Romanowska-Dixon, Bożena $u University Hospital of Krakow, Jagiellonian University, CM, Krakow, Poland
700    1_
$a Eremina, Alena $u Novosibirsk Branch of FBSI IRTC, Novosibirsk, Russia
700    1_
$a Zavgorodnya, Nataliya $u Medical Center Ltd VISUS, Zaporizhzhia, Ukraine
700    1_
$a Dusova, Jaroslava $u University Hospital Hradec Králové, Hradec Králové, Czech Republic
700    1_
$a Sagong, Min $u Department of Ophthalmology, Yeungnam University College of Medicine, Daegu, Republic of Korea
700    1_
$a Kim, Sunghyun $u Celltrion, Inc., Incheon, Republic of Korea
700    1_
$a Ahn, Keumyoung $u Celltrion, Inc., Incheon, Republic of Korea
700    1_
$a Kim, Suyoung $u Celltrion, Inc., Incheon, Republic of Korea
700    1_
$a Bae, Youngmin $u Celltrion, Inc., Incheon, Republic of Korea
700    1_
$a Lee, Sangmi $u Celltrion, Inc., Incheon, Republic of Korea
700    1_
$a Kang, Hyejin $u Celltrion, Inc., Incheon, Republic of Korea
700    1_
$a Brown, David M $u Retina Consultants of Texas, Retina Consultants of America, Houston, TX. Electronic address: dmbmd@retinaconsultantstexas.com
773    0_
$w MED00214013 $t Ophthalmology. Retina $x 2468-6530 $g Roč. 8, č. 12 (2024), s. 1163-1173
856    41
$u https://pubmed.ncbi.nlm.nih.gov/38942386 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20250121 $b ABA008
991    __
$a 20250206104243 $b ABA008
999    __
$a ok $b bmc $g 2263221 $s 1239332
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2024 $b 8 $c 12 $d 1163-1173 $e 20240626 $i 2468-6530 $m Ophthalmology. Retina $n Ophthalmol Retina $x MED00214013
LZP    __
$a Pubmed-20250121

Najít záznam

Citační ukazatele

Možnosti archivace